{"id":"W4293280727","doi":"10.1093/ckj/sfac189","title":"SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence","year":2022,"lang":"en","type":"review","venue":"Clinical Kidney Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Vifor Pharma; GlaxoSmithKline Australia; Kyowa Kirin Pharmaceutical Development; Idorsia Pharmaceuticals; Amicus Therapeutics; Novo Nordisk; AstraZeneca; Chiesi Farmaceutici; Menarini Group; Astellas Pharma US; Alexion Pharmaceuticals; Fresenius Medical Care North America; Bayer; Amgen","keywords":"Proteinuria; Albuminuria; Medicine; Nephrotic syndrome; Kidney disease; Randomized controlled trial; Internal medicine; Glycemic; Diabetes mellitus; Urology; Intensive care medicine; Kidney; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01058943,0.0007590661,0.004737273,0.0006086871,0.0002232338,0.0001465936,0.0007463912,0.0006848859,0.003367637],"category_scores_gemma":[0.01511963,0.0005642285,0.003485205,0.000859462,0.0002707502,0.0002800749,0.0006687592,0.005855347,0.0004392148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006330395,"about_ca_system_score_gemma":0.002539372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007018546,"about_ca_topic_score_gemma":0.000003014388,"domain_scores_codex":[0.9888786,0.002338778,0.005775254,0.00105007,0.001067646,0.0008896139],"domain_scores_gemma":[0.9925896,0.002560117,0.001954093,0.0009643343,0.0001011415,0.001830747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001045884,0.001324681,0.008709141,0.004929049,0.0009577949,0.002452124,0.00002287826,1.380791e-7,1.408027e-8,0.00002070916,0.0646528,0.9168261],"study_design_scores_gemma":[0.002715593,0.001677993,0.000548915,0.05240842,0.004281229,0.0002528332,0.00003269305,0.000006331409,3.022374e-8,0.0000775177,0.9375459,0.0004525441],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009103126,0.9868037,0.00001376253,0.002360524,0.005334284,0.003350635,0.00001233754,0.00008054384,0.001953226],"genre_scores_gemma":[0.00001125876,0.9884982,0.0009916507,0.00226602,0.005127667,0.0003275619,0.00006029989,0.0001406088,0.0025767],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9163736,"threshold_uncertainty_score":0.9996809,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2634811373342701,"score_gpt":0.489166837747945,"score_spread":0.2256857004136749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}